Evidence map›Paper›PMID 34413096›Full record

SynthesisBMJ open2021

Prevalence of sarcopenia in older Chinese adults: a systematic review and meta-analysis.

Caihong Xin, Xin Sun, Li Lu, Ling Shan

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 5 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 5 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Caihong XinDepartment of Endocrinology and Metabolism, Fourth People's Hospital in Shenyang, Shenyang, Liaoning, China.
Xin SunDepartment of Endocrinology and Metabolism, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.ORCID 0000-0003-1409-4661
Li LuDepartment of Endocrinology and Metabolism, People's Hospital of Liaoning Province, Shenyang, Liaoning, China.
Ling ShanDepartment of Endocrinology and Metabolism, People's Hospital of Liaoning Province, Shenyang, Liaoning, China shanling0113@163.com.ORCID 0000-0003-2019-9718
Liaoning Provincial People's Hospital · CNShenyang The Fourth Hospital of People · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis meta-analysis was conducted to estimate the overall prevalence of sarcopenia in older Chinese adults.

designSystematic review and meta-analysis.

participantsA literature research was conducted using the PubMed, Web of Science, China National Knowledge Infrastructure, CQVIP and Wanfang databases. The following search terms in the abstract were used: "sarcopenia" in combination with the terms "prevalence," "epidemiology" and "China." All studies published from January 2010 to November 2020 were included. The random-effect model was used to estimate the prevalence of sarcopenia. The sex-specific prevalence of sarcopenia at a 95% CI was also calculated using different criteria for defining sarcopenia. PRIMARY OUTCOME MEASURES: The overall prevalence of sarcopenia in older Chinese adults.

resultsIn total, 23 articles were included in this meta-analysis involving 21 564 participants. On the basis of the Asian Working Group for Sarcopenia criterion, the overall prevalence of sarcopenia among the elderly in China was 14% (95% CI 11% to 18%); the prevalence was higher in Chinese women than in men (15% vs 14%).

conclusionsThis systematic review is the first estimation of the pooled prevalence of sarcopenia in older Chinese adults. Our results suggest that China has a large number of patients with sarcopenia. These findings would be useful for sarcopenia prevention in China. There is a high degree of heterogeneity, and although there are a large number of cases and could be an emerging public health issue, more research is required to make these claims. PROSPERO REGISTRATION NUMBER: CRD42020223405.

Indexed as

SarcopeniaAdultAgedAsian PeopleChinaFemaleHumansMaleMiddle AgedPrevalenceepidemiologygeneral endocrinologygeriatric medicine

Identifiers

PMID34413096
PMCPMC8378367
OpenAlexW3195354595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.